Gene, Cell, & RNA Therapy Landscape Report

The Gene, Cell, & RNA Therapy Landscape report, created in partnership with Citeline, is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.

Q4: First U.S.-Approved Gene Therapies for SCD

In Q4 2023:

  • FDA approved two cell-based gene therapies, Casgevy and Lyfgenia, to treat sickle cell disease

  • Casgevy is the first approved therapy in the U.S. that uses CRISPR

  • Two RNA therapies were also approved in the U.S.

 

Report Archives

2023 Archive

Read all the landscape reports from 2023.

2022 Archive

Read all the landscape reports from 2022.

2021 Archive

Read all the reports from 2021 here.

2024

Register for the 27th Annual Meeting

May 7-11, 2024 | Baltimore, MD